Manuel
Barreiro de Acosta
Hospital de Cruces
Barakaldo, EspañaPublicacións en colaboración con investigadores/as de Hospital de Cruces (28)
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making
Digestive Diseases, Vol. 41, Núm. 6, pp. 879-889
2022
-
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Inflammatory bowel diseases
-
Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)
Inflammatory Bowel Diseases
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Inflammatory bowel diseases, Vol. 28, Núm. 1, pp. 41-47
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study
Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2020
-
Early microscopic findings in preclinical inflammatory bowel disease
Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472
-
Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study
BMJ Open Gastroenterology, Vol. 7, Núm. 1
2019
-
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study
Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002
2018
-
Characteristics and Progression of Preclinical Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466
-
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients
Gastroenterologia y Hepatologia
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279